16 January 2026 – The National Nanotechnology Center (NANOTEC), under the National Science and Technology Development Agency (NSTDA), welcomed a delegation from the Pharmaceutical Plant in the Royal Initiative of the Chulabhorn Royal Academy for a research visit and strategic discussion on pharmaceutical innovation and collaboration.
Led by Dr. Urcha Rakstanonchai, Executive Director of NANOTEC, the meeting focused on strengthening cooperation to build a national ecosystem for the development of high-quality cancer medicines for Thailand, leveraging advanced nanotechnology and sustainable manufacturing approaches.
During the visit, NANOTEC presented its research capabilities in nanotechnology-enabled drug delivery systems, highlighting technologies that enhance the efficacy, safety, and targeted delivery of pharmaceuticals, herbal medicines, and biologics. The research focuses on precise encapsulation and controlled release mechanisms aimed at improving therapeutic outcomes while reducing side effects, with applications spanning medicines, vaccines, and medical products for both human and veterinary use.
NANOTEC also showcased its expertise in advanced water treatment and filtration technologies, demonstrating integrated solutions for water quality monitoring, pollution control at source, and efficient wastewater treatment. Particular emphasis was placed on the development of advanced materials capable of removing small-molecule contaminants, including antibiotic residues, from water systems—an essential component of environmentally responsible pharmaceutical manufacturing.
The discussion underscored Thailand’s need to reduce reliance on imported pharmaceuticals and active pharmaceutical ingredients (APIs). By integrating NANOTEC’s strengths in nanomaterials, drug delivery, and environmental technologies, the collaboration aims to support domestic production of high-quality cancer medicines, promote sustainable manufacturing, and enhance national pharmaceutical security for the benefit of Thai society.
